
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.
Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert reviews the epidemiology, clinical presentation, and differential diagnoses of AD in children, as well as the inflammatory processes driven by type 2 cytokines that lead to AD and its atopic comorbidities

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.
Dr. Jonathan Spergel and Prof. Arjan Bredenoord highlight the importance of different immune cells in type 2 inflammation in EoE.

Highlights from the ADVENT educational symposium at EADV 2024 where Professors Eric Simpson, Stephan Weidinger, and Marjolein de Bruin-Weller explored the local and systemic effects of type 2 inflammation in AD and potential benefits of early intervention with regard to disease modification.